In this study of 421 patients with AMI-CS evaluating the effectiveness and safety of pre-treatment with P2Y12 inhibitors, the main findings were as follows: firstly, pre-treatment with P2Y12 inhibitor was administered in half of the patients with AMI-CS before reaching the catheterization laboratory; secondly, absence of pre-treatment with oral P2Y12 inhibitor was not associated with a higher risk of MACE; thirdly, pre-treatment with P2Y12 inhibitor was associated with a greater risk of major bleeding complications at 30 days. The gene discussed is P2RY12; the disease is Cowden syndrome 1.